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1. Introduction 
Since the demonstration of double stranded DNA structure by Watson and Crick in 1953, 
knowledge about DNA structure and sequences has accumulated (Alberts et al., 2008). 
Although DNA contains complex genetic information in a very stable manner, DNA 
sequence and/or structure are sometimes disrupted. Previous research on the damage and 
repair mechanisms of DNA complex showed the existence of various types of DNA damage 
as well as the presence of sophisticated processes utilized by the cells to maintain the 
integrity of genome. DNA damage can be defined as any changes in the genomic integrity 
due to the disruptive impact of any exogenous and endogenous factors. Interestingly, it has 
been shown that damage to DNA is a usual event which is also underlying cause of many 
disorders including certain mutations and deletions leading to cancer and other inherited or 
acquired pathologies. 
There are many endogenous and exogenous sources which cause DNA damages interfering 
with genome. Endogenous factors emerge from the DNA replication as well as recombination 
(Martin, 2008a). Although some of the exogenous factors may directly react with DNA, some 
of them tend to cause DNA damage by indirect route. Oxidation damage, alkylation of bases, 
hydrolysis of bases and replication errors are considered to be endogenous factors. Ultraviolet 
light, ionizing radiation and environmental chemical agents are among the exogenous factors.  
1.1 Damage exerted by endogenous factors 
1.1.1 Oxidative damage to bases 
Normal metabolic events and external factors can lead to the formation of reactive oxygen 
species (ROS). ROS are molecules that contain an unpaired electron in their utmost outer 
orbital, which makes them very reactive. Generally, the ROS are superoxide (O2-.), hydrogen 
peroxide (H2O2), singlet oxygen (1O2) and hydroxyl radicals (.OH). These agents can oxidize 
DNA, causing damage such as oxidized bases, single strand and double strand breaks.  
Oxidatively damaged nucleotides can be found common in cells despite the extensive DNA 
repair. Not surprisingly, the amount of this damage is higher in cancer cells (Iida et al., 
www.intechopen.com
 
DNA Repair and Human Health 
 
280 
2001). There are various ways by which the cell can endure the damage or decrease the 
number of the ROS (Slupphaug et al., 2003). Oxidative stress is observed when the natural 
antioxidant capacity of the cell cannot tolerate the ROS production. This results in the 
damage of the macromolecules such as DNA, proteins and lipids. ROS also affects the 
antioxidant enzymes as well (Tabatabaie et al., 1994). Studies have emphasized that any 
increase in the endogenous ROS generation or decrease in cellular antioxidants increases the 
mutation rate and inevitably raise the risk of cancer. Consuming antioxidant- rich diet has 
been proven to decrease the risk of cancer (Loft & Poulsen, 1996).  
1.1.2 Alkylation of bases: Methylation 
Oxygen is not the only reason of DNA damage in cells. Alkylating agents such as S-
adenosylmethionine (SAM), which is a reactive methyl group donor, play significant roles in 
DNA damage. SAM methylates DNA, which is important for regulation of gene expression 
(Holliday & Ho, 1998) (Fig. 1). Endogenous methylation can also be carried out by betaine, 
choline and simple alkylating agents. Although this may occur endogenously, they might 
also be obtained from exogenous sources by environmental pollution and/or tobacco.  
Most frequently, DNA methylation generates 7-methylguanine and 3-methyladenine. 
Having no effect on the coding specificity of the base, 7-methylguanine can be considered as 
less harmful (Zhao et al., 1999). However it can cause the blocking of DNA replication by the 
destabilization of the glycosyl bond. 3-methyladenine also blocks replication. DNA 
glycosylase is present in all living cells, removing 3-methyladenine from DNA. However, 
this action is found to be decreasing by age. 7-methylguanine repair is very insufficient and 
its accumulation can be observed in mammalian DNA (Atamna et al., 2000).  
 
 
Fig. 1. Alkylation of bases 
1.1.3 Hydrolysis of bases: Deamination, depurination / depirimidation 
Hydrolytic damage causes depurination, depyrimidination, and deamination of bases. The 
glycosidic bond in DNA structure is prone to breakage under heating, alkylation of bases or 
N-glycosylase activity (Lindahl et al., 1982). An abasic site is the result of the glycosidic 
bond cleavage in DNA. Apurinic (AP) sites can be produced spontaneously or by the effect 
of ROS (Nakamura et al, 2000). Abasic sites are among the most common endogenous 
lesions estimated to be 10 000 lesions/ cell/day. Hydrolytic deamination takes place 
frequently in DNA bases; however it is more frequent in single stranded DNA than double 
stranded. Deamination and methylation processes affect amino containing bases, cytosine, 
and adenine. In a cell, daily between 100 to 500 cytosines are deaminated to uracil. 
Deamination and methylation converts cytosine into uracil and/or mutant thymidine 
leading to wrong base pairs (Lindahl, 1993). 
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Human cells lose about 5000 adenines or guanines everyday because of spontaneous base-
sugar link fissions. Less frequently, adenines spontaneously deaminate to give hypoxanthine 
(Alberts et al., 2008). 
1.1.4 Errors in replication  
In humans, 107 cells divide every second and it is estimated that one-third of these 
spontaneous mutations take place. These mutations are caused by mistakes in DNA 
replication and the copying of damaged templates by DNA polymerases. Scientists things 
that, errors mostly coused by mispairing of bases with different nature. This means pairing 
of nontautomeric chemical forms of different bases or pairing of normal bases but mismacth 
which is caused by a little shift of nucleotide positions. This mispairing is named as wobble 
and it occurs because the flexiblelty of DNA double helix (Crick, 1966). 
Any undetected error in replication will lead to mutant cell due to mismacth, (for example, 
mutant strand containing CG instead of AT). Fortunately, rate of replication error is as low 
as 1/105 and with proof-reading mechanism this rate reduces up to 1/107-1/109 (Johnson et 
al., 2000). 
1.2 Damage exerted by exogenous factors: Exogenous factors are composed of two 
main sources 
1.2.1 Physical factors: UV light and ionizing radiation 
Ultraviolet (UV) radiation, as a physical factor, is of solar origin and one of the most powerful 
exogenous agents disrupting genomic sequence. UV light is composed of three subtypes, UV-
A, UV-B, UV-C. All has different wavelengths resulting in various effects on DNA. Compared 
with UV-A, UV-B has shorter wavelength (280-315 nm) and a more direct effect on DNA. It 
modifies chemical composition of DNA by forming dimers which disrupts molecular 
composition (Rastogi, 2010). TT dimerization is the most encountered form of UV-related 
damage. Thymidine dimers interfere with DNA replication by changing DNA polymerase 
(Arlett et al., 2006). Fortunately, UV-B radiation occupies a very small part of total solar 
energy. UV-A has weaker impact on DNA sequence because of its poor absorption by DNA. 
But, it tends to produce 1O2 which can disrupt DNA sequence. This way is the indirect 
damaging of UV-A light on DNA. UV-C does not lead to considerable hazard on cells owing 
to its high absorption in atmosphere. 
Radiation is also known to interfere with genome integrity. The mechanisms of the damage 
to DNA are as follows ; 
- Rupture of the strand: It can divide as single or double strand breaks. Single strand breaks 
(SSBs) may occur at the phosphodiester bond, or at the bond between the sugar and the 
base. A large proportion of the SSBs are caused by OH. . Double strand breaks (DSBs) 
involve breakage of both strands and are directly proportional to the radiation dosage. 
- Alteration of bases: Bases can be damaged or destroyed by radiation. Among the bases, 
pyrimidines (T, C) are more vulnerable to radiation than purines. 
- Destruction of sugars. 
- Cross-links and formation of dimers (Alberts et al., 2008). 
1.2.2 Chemical agents 
Over a century, exposure to chemical agents has been known to induce cancer. After many 
studies on individuals who work with chemicals or exposed to the chemicals, researchers 
demonstrated the basic principles of chemical carcinogenesis. This chemicals establish 
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covalent bounds with bases on DNA and create DNA adducts. This structure is accepted as 
beginning of carcinogenesis (Poirier, 2004). Chemicals can cause other DNA disruption 
except adducts like strand cross-links, breakages and deletions. Some important chemical 
agents are; tobacco-specific N-nitrosamine, benzidine, aromatic amines, asbestos, benzene, 
aflatoxins, polycyclic aromatic hydrocarbons (Poirier, 2004, Loeb & Harris, 2008). 
Aflatoxins are toxic metabolites of fungi and are carcinogenic in several animal species 
though with variable potency (CJ Chen & DS Chen, 2002, Zhang, 2010). Aflatoxin B1 (AFB1) 
which is a very toxic Aflatoxin type is a secondary metabolite of Aspergillus flavus and 
Aspergillus parasiticus and is known to be a human hepatocarcinogen (Zhang, 2010, Wogan 
& Newberne, 1967, Wogan, 1976, 1987, 1992). It may contaminate various food resources, 
which include but is not limited to, cereals such as rice, wheat and maize, as well as corn 
and peanuts which are stored in warm and humid places (Zhang, 2010, Wogan, 1976, Toteja 
et al., 2006, Matumba et al., 2009). AFB1 forms DNA adducts with guanine in the DNA of 
human hepatocytes and is thought to cause G: C to T: A transversion mutations, that acts as 
a cause of hepatocellular carcinogenesis (Hussain et al., 2007) 
2. DNA repair mechanisms 
In response to genotoxic stress, which can be mainly caused by various chemicals, reactive 
cellular metabolites and ionizing or UV radiation, DNA repair pathways and cell cycle 
checkpoints can be activated, allowing the cell to repair or prevent the transmission of 
damaged or incompletely replicated chromosomes. The balance between cell cycle arrest, 
DNA repair and the initiation of cell death could determine if DNA damage is compatible 
with cell survival or requires elimination of the cell by apoptosis. Defects of DNA repair 
pathways and cell cycle checkpoints may cause susceptibility to DNA damage, genomic 
defects, hypersensitivity to cellular stress and resistance to apoptosis, which characterize 
cancer cells (Ishikawa et al., 2006). 
Major DNA repair pathways are base excision repair (BER), nucleotide excision repair 
(NER), mismatch repair (MMR), homologous recombinational repair (HR) and non-
homologous end joining repair (NHEJ). These pathways each require a number of proteins 
and enzymes. By contrast, the direct removal of small alkyl groups (such as methyl groups) 
specifically from the O6 position of guanine and the O4 position of thymine in DNA is 
produced by the action of a single enzyme, O6-methylguanine-DNA methyltransferase 
(MGMT) (Fleck & Nielsen, 2004). 
2.1 Base excision repair (BER) 
BER is characterized by the excision of nucleic acid base residues in the free form (Friedberg 
et al., 1995). Conversely, NER removes damaged nucleotides which are approximately 30 
nucleotides long. The primary and initiating event of BER is the hydrolysis of the N-glycosyl 
bond, therefore releasing the free base. This hydrolysis in DNA is catalyzed by a class of 
enzymes called DNA glycosylases (Fiedberg & Wood, 1996). 
BER principally repairs non-bulky lesions produced by oxidation, alkylation or deamination 
of bases. Cells contain various DNA glycosylases, each of them showing a specific substrate 
spectrum. After hydrolysis of the N-glycosylic bond by a DNA glycosylase, the damaged 
base is released and an apurinic or apyrimidinic site (AP site) is produced. An AP site can 
also form spontaneously and represents damage itself (Fleck & Nielsen, 2004). The repair of 
base loss in these sites utilizes a specific class of endonucleases designated as AP 
endonucleases. APE1 is the major human AP endonuclease (Friedberg et al., 1995). Two 
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pathways can repair the AP site formed by a DNA glycosylase: These are short-patch BER 
(SP-BER) and long-patch BER (LP-BER) pathways. SP-BER involves a single nucleotide 
replacement followed by ligation (Hoeijmakers, 2001). DNA ligase III interacts with XRCC1, 
Polǃ and poly(ADP-ribose) polymerase-1(PARP-1 ) and is involved only in short-patch BER 
(Kubota et al., 1996). LP-BER involves DNA synthesis of multiple nucleotides (usually 2–6 
nucleotides) (Hoeijmakers, 2001). The LP-BER depends on factors which are normally 
involved in DNA replication: DNA polymerase ǅ (POLǅ) or ǆ (POLǆ), proliferating cell 
nuclear antigen (PCNA) and replication factor C (RFC) (Izumi et al., 2003; Sung & Demple, 
2006). In LP-BER, the replaced strand does not exposed to degradation during 
polymerization but rather is displaced and cut away by DNAase IV or flap endonuclease 1 
(FEN1), whereas the ligation step is performed by Ligase I (LIG1). LP-BER is usually used in 
yeast cells whereas SP-BER is generally used in mammalian cells (Altieri et al., 2008).  
2.2 Nucleotide excision repair (NER) 
NER mainly repairs bulky DNA adducts, such as UV-light-induced photolesions [(6-4) 
photoproducts (6-4PPs) and cyclobutane pyrimidine dimers (CPDs)], intrastrand cross-links, 
large chemical adducts generated from exposure to aflatoxine, benzo[a]pyrene and other 
genotoxic agents (Christmann et al, 2003). The names of many of the genes found in NER, 
start with the letters “XP,” because they were first identified in human DNA-repair disease, 
Xeroderma pigmentosum (XP) (Altieri et al., 2008). NER consists of two repair subpathways: 
Global genome repair (GGR) and transcription-coupled repair (TCR). GGR removes damage 
in the whole genome whereas TCR specifically repairs the transcribed strand of active genes 
(Fleck & Nielsen, 2004).  
2.2.1 Global genome repair (GGR) 
The XPC/HR23B is the first NER factor to detect a lesion and recruit the repair machinery to 
the damaged site in GGR (Kusumoto et al., 2001). Another factor which participates the 
recognition of the damage is UV-DDB (UV-damaged–DNA-binding protein), consisting of two 
proteins, DDB1 and DDB2 (also known as XPE) (Altieri et al., 2008). The transcription factor 
transcription factor IIH (TFIIH) is also recruited to the site of DNA damage (Yokoi et al., 2000). 
The binding of TFIIH is mediated by its p62 subunit which specifically interacts with 
XPC/HR23B, thus allowing the recruitment of TFIIH to the damaged site (Altieri et al., 2008). 
TFIIH harbors DNA helicase activity, which is exerted by its helicase subunits XPB and XPD 
(Schaeffer et al., 1993; Schaeffer et al., 1994). It is responsible for unwinding of DNA around the 
lesion (Evans et al., 1997a). Except the unwinding function, it is also responsible for the 
recruitment of XPA and XPG. The initial unwinding by XPB helicase opens up a small region 
and permits access of XPA to the damaged region. XPA also interacts with many other NER 
components like TFIIH, RPA and ERCC. The binding of XPA to TFIIH allows the complete 
unwinding of DNA helix to generate an open stretch of approximately 20-30 nucleotides, with 
the action of RPA. RPA is the major single-stranded DNA-binding protein required for 
eukaryotic metabolism. It is involved in many processes like DNA repair, replication, and 
recombination. RPA facilitates DNA unwinding by TFIIH through its ssDNA binding activity. 
After the interaction with XPA, RPA binds to the single, undamaged strand thus protecting it 
from nuclease attack (Lee et al., 2003). After binding of RPA and XPA, XPC/HR23B is released, 
allowing its recycling for other damaged sites where the repair mechanism must start (Altieri 
et al., 2008). After damage recognition and the formation of an open complex, removal of the 
lesion is performed by bidirectional incisions at determined positions flanking the DNA 
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damage (Evans et al., 1997b). 3'-incision is carried out by XPG (O’Donovan et al., 1994), and 5'-
incision is performed by the XPF–ERCC1 complex (Sijbers et al., 1996). The arising DNA gap is 
filled in by the action of Polǅ and Polǆ and sealed by DNA ligase I and accessory factors 
(Araujo et al., 2000; Mu et al., 1995). 
2.2.2 Transcription-coupled repair (TCR) 
Transcription-coupled repair (TCR) is specifically removes DNA lesions in the genomic 
region where transcription is occurring simultaneously. Nowadays, it is not very clear how 
repair is coupled with active transcription, but it is generally supposed that a stalled 
transcript provides a strong signal to attract the repair mechanism. In this situation, the 
recognition factors intercede the dissociation of RNA polymerase II (RNAPII) from the DNA 
strand to allow the repair process to continue (Sarasin & Stary, 2007). Slow removal of DNA 
lesions from transcription templates would prevent efficient transcription. XPB, XPD (as 
part of TFIIH), XPG, CSA and CSB are essential for TCR (Le Page et al., 2000; Schaeffer et al., 
1993). The reduction of transcription in CSB cells upon UV irradiation is caused by blockage 
of RNAPII at the photoproduct regions (Selby et al., 1997). When RNAPII is inactivated at 
the site of DNA lesions, CSA and CSB mediate the activation of NER pathway by release of 
the stalled RNAPII elongation complex from the damaged DNA. GGR and TCR could be 
related through a direct interaction of CSB and XPG (Iyer et al., 1996).  In humans, TCR 
requires all the proteins needed for GCR except XPC, XPE and HR23B. The following steps 
of TCR are actually the same as for GCR with the development of the open complex and the 
lesion demarcation by XPA, RPA, and TFIIH, the excision of damaged strand, the filling by 
DNA polymerase, and the sealing of DNA fragments by a DNA ligase (Altieri et al., 2008). 
2.3 Mismatch repair (MMR) 
MMR is a type of DNA repair mechanism that targets base substitution and insertion/deletion 
mismatches resulting from errors formed during DNA replication and escaped from the 
proofreading activity of DNA polymerases, an event occurring with a frequency of 
approximately 1 in 109–1010 base pairs per cell division (Iyer et al., 2006). It is responsible for 
removal of these base mismatches which are caused by spontaneous and induced base 
deamination, methylation, oxidation and replication errors (Christmann et al., 2003). 
MMR is well understood in E. coli, where the core enzymes of the repair system are the 
products of the mutH, mutL, and mutS genes. MMR can only protect cells from permanent 
mutations if the parental strand which contains the correct information can be accurately 
separated from the daughter strand. In E. coli, the strand discrimination signal is achieved 
by adenine methylation in GATC sequences. Newly replicated DNA is not still methylated 
on the daughter strand (Modrich, 1991; Friedberg et al., 1995). Thus MutH recognizes the 
temporarily unmethylated newly synthesized DNA strand and cleaves it at hemimethylated 
GATC sites which are located within 1,000 bp of the mismatch (Altieri et al., 2008). MutL 
protein mediates communication between the bound MutH and MutS products (Modrich, 
1991). MutL also recruits UvrD at the damage site (Altieri et al., 2008). UvrD helicase and 
RPA generates a ssDNA filament containing the mismatched base, which is then cleaved by 
nuclease activities. Ultimately, DNA polymerase III refills the gap truly and DNA ligase III 
seals the last nick (Kunkel & Erie, 2005).  
All eukaryotic organisms have MutS and MutL homologues, MSHs and MLHs, respectively. 
Five MSHs (MSH2–MSH6) are present in both yeast and mammals, whereas MSH1 exists 
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only in yeast. MSH2 is required for all mismatch correction in nuclear DNA, whereas MSH3 
and MSH6 are required for the repair of some distinct types of mismatched DNA during 
replication. MSH4 and MSH5 are probably involved in meiotic recombination. Mammalian 
cells have two MutS activities that function as heterodimers and share MSH2 as a common 
subunit: MutSǂ (MSH2–MSH6 heterodimer) and MutSǃ (MSH2–MSH3 heterodimer) (Jascur 
& Boland, 2006; Modrich, 2006). Eukaryotic cell does not contain MutH protein. In this 
situation the problem is to find an entry point for the strand excision activities. The solution 
seems to rely on using nicks or gaps left behind by the progressing replication forks, which 
may explain the respective role of PCNA in MMR (Kunkel & Erie, 2005). Finally, the 
excision of the DNA strand which contains the mispaired base is carried out by exonuclease 
I (Genschel et al., 2002) and the new synthesis by Polǅ (Longley et al., 1997). 
2.4 Double strand break repair (DSBR) 
DNA DSBs are the most damaging lesions in the genome. They can form as a result of 
several damaging agents including ionizing radiation (IR) or chemical exposure (Ataian & 
Krebs, 2006). The major difference between DSBs and many other types of DNA lesions, 
including SSBs, is that in DSBs both DNA strands are damaged, which impedes the use of 
the complementary strand as template in the repair process (Genovese et al., 2006).  
The two major pathways used by cells to repair DNA DSBs are homologous recombination 
(HR) and non-homologous end-joining (NHEJ). HR is an error-free pathway which is 
usually found in simple eukaryotes (Cromie et al., 2001). Conversely, NHEJ is an error-
prone pathway which is usually predominates in mammals (Dasika et al., 1999).  
2.4.1 Homologous recombinational repair (HR) 
HR is initiated by a nucleolytic excision of the DSB in the 5'–3' direction by the MRE11–
RAD50–NBS1 (MRN) complex (Christmann et al., 2003). In the development of MRN 
complex, MRE11 and RAD50 produce the core complex and then they interact with NBS1. 
MRE11 has got various biochemical properties, such as DNA exonuclease activity, which 
can be stimulated by RAD50, DNA unwinding activity and single-strand DNA 
endonuclease activity. Contribution of MRN complex to DSB sites is supported by the 
binding of NBS1 to phosphorylated histone-H2AX. After DNA strand excision and protein 
binding, heteroduplex DNA is formed. This process requires BRCA2 and RAD51. BRCA2 is 
assigned in controlling the recombinase activity of RAD51 and its loading onto single-
stranded DNA (Altieri et al., 2008). RAD51 is assisted by a number of protein factors 
including RAD52, RAD54, BRCA1 and RAD51 prologues (Rad51B, Rad51C, Rad51D, 
XRCC2, XRCC3) (Fleck & Nielsen, 2004). Afterwards the resulting 3' single-stranded DNA is 
bound by a heptameric ring complex formed by RAD52 proteins (Stasiak et al., 2000), which 
protects against exonucleolytic digestion. For binding of DNA ends, RAD52 competes with 
the Ku complex. This situation may determine whether the DSB is repaired by the HR or the 
NHEJ pathway (Van Dyck et al., 1999). RPA is another important protein that interacts with 
RAD51 (Golub et al., 1998). Interaction of RAD51 with RPA stabilizes RAD51-mediated 
DNA pairing by binding to the displaced DNA strand (Eggler et al., 2002). Thus, RAD51 
catalyzes strand-exchange process with the complementary strand in which the damaged 
DNA invades the undamaged DNA duplex, displacing one strand as D-loop (Baumann & 
West, 1997; Gupta et al., 1998). After D-loop formation, the annealed 3'-end is then extended 
by repair synthesis through the original break site to restore the missing sequence 
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information at the break point. The sister chromatid provides a proper template for such 
error-free repair synthesis, actually it is the preferred template for homology-directed repair. 
On the other side of the D-loop, an “X” like structure, known as Holliday junction, is formed 
at the border between hetero- and homoduplex. If the Holliday junction is transported in the 
same direction as replication, it will release strand which is newly synthesized. Once repair 
synthesis is complete, the next step is to release the newly synthesized end, which can be 
performed by sliding the Holliday junction toward the 3'-end. Then the two broken ends 
reconnect. This process is facilitated by RAD52 and promoted by the annealing of 
complementary sequences. This process may generate gaps or flaps, depending on the 
degree of 3'-end extension during repair synthesis. Flaps can be removed by XPF/ERCC1 
complex also remaining gaps are filled and sealed by PCNA-dependent DNA polymerase 
ǅ/ǆ and DNA ligase I (Altieri et al., 2008).  
2.4.2 Non-homologous end joining repair (NHEJ) 
The term “non-homologous” is used to describe this repair pathway. Also in this pathway 
1–6 bp region of sequence homology (microhomology) near the DNA end frequently 
facilitates rejoining (Helleday et al., 2007). In contrast to NHEJ, HR is directed by longer 
stretches of homology (>100 bp) therefore the major difference between NHEJ and HR is the 
span of homologous sequences associated with repair process (Altieri et al., 2008). 
In the first step heterodimeric complex consisting of the proteins Ku70 (Reeves & Sthoeger, 
1989) and Ku80 binds to the damaged DNA, thus protecting the DNA from exonuclease 
digestion (Altieri et al., 2008). Then the DNA–Ku complex attracts and activates the catalytic 
subunit (DNA-PKcs), a serine/threonine protein kinase. DNA-PKcs is autophosphorylated 
after juxtaposition of the two DNA ends (Helleday et al., 2007). If further processing of ends is 
not required, the complex attracts the additional core components, XRCC4, LIG4 and XLF, 
which together form the ligase complex and seal the DNA ends. In the presence of 3'- and 5'-
overhangs, hairpins, gaps and flaps, characterized by single-strand/double-strand transitions 
DNA end joining requires an additional end processing before sealing (Altieri et al., 2008). 
Processing of DSBs is mainly performed by the MRN complex (Nelms et al., 1998) which has 
endonuclease, exonuclease, and helicase activity (Paull and Gellert, 1999) and removes excess 
DNA at 3' flaps. Flap endonuclease 1 (FEN1) is one of the candidate responsible for removal of 
5′ flaps (Wu et al., 1999). Other factors which are needed for processing includes structure-
specific Artemis nuclease and/or the DNA polymerases POLμ, POLλ, and TdT (Altieri et al., 
2008). Artemis acts in a complex with DNA–PK (Moshous et al., 2001). It also displays single-
strand-specific exonuclease activity (Ma, 2002). In this process, Ku heterodimer interact with 
Artemis, and the LIG4/XRCC4 complex, thus organizing the activities and the reversible 
interaction of the processing factors with the core components (Altieri et al., 2008). 
3. Cell cycle checkpoints 
Cell cycle checkpoint signaling is activated in response to incomplete DNA replication due 
to DNA damages induced by both internal and external sources such as UV light, reactive 
oxygen species, ionizing radiation or DNA damaging chemotherapeutic agents. Active 
checkpoints prevent further progression during the cell cycle. If the genotoxic stress exceeds 
repair capacity, additional signaling pathways may cause cell death, probably via apoptosis. 
(Reinhardt & Yaffe, 2009b). If the damage level is low, the cell can deal with the lesions so it 
www.intechopen.com
 
DNA Repair, Cancer and Cancer Therapy 
 
287 
does not need to activate the checkpoint signaling. If the lesions are not rapidly repairable or 
if damage level is high, checkpoint signaling mechanisms take place for cell survival and 
protection of genome integrity (Lazzaro et al., 2009). Cells can arrest at cell cycle checkpoints 
to allow for: (1) repairing of cellular damage; (2) the dissipation of an exogenous cellular 
stress signal; or (3) availability of required hormones, growth factors or nutrients (Pientepol 
& Stewart, 2002). Thus cell cycle checkpoints provide more time for repair of DNA damage 
before DNA replication and mitosis (Kaufmann & Paules, 1996).  
3.1 G1/S checkpoint 
In the presence of DNA damage, the G1/S checkpoint prevents replication of damaged DNA 
through two different signal transduction pathways. The first pathway involves the 
degradation of Cdc25A phosphatase. Chk2 and Chk1 activated by ATM and ATR 
phosphorylate Cdc25A, which is then degraded by the ubiquitin proteasome pathway 
(Shimada & Nakanishi, 2006). Cdc25A degradation results from the inactivation of Cdk2 
and prevents Cdc45 from loading onto chromatin (Arata et al., 2000). Cdc45 is required for 
the recruitment of DNA polymerase α, thus lack of Cdc45 incorporation into the chromatin 
structure inhibits new origin firing. This pathway plays a role in the initial G1/S checkpoint 
arrest. In order to maintain this arrest, transcriptional responses are mediated by p53 
(Shimada & Nakanishi, 2006). ATM and ATR phosphorylate p53 at Ser15 (Banin et al, 1998; 
Canman et al, 1998), which inhibits the interaction of p53 with MDM2 (Shieh, 1997), thus 
p53 is stabilized. ATM also phosphorylates MDM2 on Ser395 and decreases the probability 
of an interaction between MDM2 and p53, thus p53 is accumulated (Maya et al., 2001) 
Stabilization and increased transactivation activity of p53 leads to the induction of p21, 
which inhibits the Cdk2–cyclin E–PCNA complex, thereby inhibiting G1/S transition 
(Mailand et al., 2000). p21 also binds to the cyclin D–Cdk4 complex and prevents it from 
phosphorylating Rb, thus suppressing the Rb/E2F pathway (Nakanishi et al., 2006). 
Therefore, degradation of cyclin D1 which is a subunit of the cyclin-dependent kinase cdk4, 
is the critical step in promoting a rapid arrest in G1. When cyclin D1 disappears, p21 is 
released from cdk4 complexes and binds rather than cdk2 complexes, preventing 
progression of cell cycle from G1 into S phase (Walworth, 2000). In summary, the G1/S 
checkpoint response targets two independent and critical tumor suppressor pathways, p53 
and pRb, which are most commonly deregulated in cancers (Nakanishi et al., 2006) 
3.2 S phase checkpoint 
In the S phase, genotoxic stress can arise from DNA-damaging insults or from difficulties 
with the replication process. S-phase checkpoints are catergorized into three types: (1) the 
replication-dependent intra-S-phase checkpoint (commonly named as replication 
checkpoint); (2) the replication-independent intra-S-phase checkpoint (generally named as 
intra-S-phase checkpoint), which can be induced by double strand breaks; and (3) the S-M 
checkpoint, which is also depends on DNA replication (Bartek et al., 2004). In the initiation 
of DNA damage checkpoints activity, the first step is the recognition of DNA damage. 
Studies in yeasts and mammals have demonstrated that RAD9, RAD1, HUS1 and RAD17 
are required factors that activate checkpoint signaling (Melo & Toczyski, 2002). RAD9, 
RAD1 and HUS1 form a heterotrimeric complex which is known as 9-1-1 complex. RAD17 
interacts with four small RFC subunits (Rfc2, Rfc3, Rfc4 and Rfc5) to form an RFC-related 
complex. When DNA is damaged, the 9-1-1 complex is recruited to the damage site under 
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the regulation of the RAD17 complex (Melo et al., 2001). In this process chromatin-bound 9-
1-1 complex facilitates phosphorylation mediated by ATR and ATM (Nakanishi et al., 2006). 
During the S-phase, damaged DNA inhibits replicative DNA synthesis (intra-S checkpoint). 
This checkpoint is regulated by two distinct pathways, known as ATM/ATR–Chk1/Chk2–
Cdc25A and ATM–NBS1–SMC1 (Falck et al., 2002). Depending on the type of DNA damage, 
ATM or ATR phosphorylates Chk2 or Chk1, respectively, resulting in the phosphorylation 
and degradation of Cdc25A (Shimada & Nakanishi, 2006). Downregulation of Cdc25A 
subsequently causes inactivation of the S-phase-promoting cyclin E/Cdk2 and prevents 
loading of Cdc45 on replication origins. The phosphorylation of NBS1 on S343 by ATM is 
required for activation of the MRN complex and the intra-S checkpoint (Lim et al., 2000; 
Zhao et al., 2000). Depending on the phosphorylation state of NBS1, SMC1 is 
phosphorylated on Ser-957 and Ser-966 by ATM which is required for the intra-S checkpoint 
(Kim et al., 2002; Yazdi et al., 2002). Other mediator proteins, such as 53BP1, BRCA1 and 
MDC1, are also involved in the intra-S checkpoint by regulating the phosphorylation of 
downstream proteins such as Chk1, Chk2, and NBS1 (Shimada & Nakanishi, 2006). 
3.3 G2/M checkpoint 
The G2/M checkpoint prevents cells from entry into mitosis through the inhibition of 
cyclinB/Cdc2 kinase by Chk1/Chk2, p38-mediated subcellular sequestration, degradation, 
and inhibition of the Cdc25 family of phosphatases. The initiation of G2/M arrest is also 
carried out with p53 (Shimada & Nakanishi, 2006). After DNA damage, members of the PI-
3K family initiate signal transduction pathways that regulate DNA repair and cell cycle 
progression. Various members of the PI-3K family can directly phosphorylate p53, including 
DNA-PK, ATM, and ATR. ATM-dependent signaling also results in activation of the Chk1 
and Chk2 kinases (Pientepol & Stewart, 2002). Following DNA damage, the ATM–Chk2–
Cdc25A and/or the ATR–Chk1–Cdc25A pathways are activated. 53BP1, MDC1, BRCA1 also 
play roles in the activation of Chk1 and Chk2 (Chan et al., 1999). MDC1 functions as a 
molecular bridge between histone Ǆ-H2AX and NBS1 in the MRN complex (Nakanishi et al., 
2006). Phosphorylated Cdc25A cause the degradation and inactivation of cyclinB/Cdc2. 
Many studies suggest that Chk1 and Chk2-mediated phosphorylation of p53 may be a 
crucial role for stabilization of the protein after DNA damage (Hirao et al., 2000; Shieh et al., 
2000). The major targets of p53 at G2/M checkpoint are the Cdk inhibitor p21, GADD45, 
which causes the dissociation of the Cdc2 and cyclin complex, and 14-3-3 sigma, which 
sequesters the cyclin B/Cdc2 complex in the cytoplasm (Chan et al., 1999). Two isoforms of 
MAP kinase, p38 ǂ and Ǆ are also implicated in the G2/M checkpoint by the regulation of 
Cdc25B and Chk2, respectively. Cells which require these genes and enzymes exhibit a 
G2/M checkpoint defect (Shimada & Nakanishi, 2006). 
4. Polymorphisms of DNA repair genes 
Many of the hereditary diseases with cancer predisposition are known to be caused by 
germ-line mutations of DNA repair genes (Paz-Elizur et al, 2008, Au, 2006). DNA repair 
deficiencies are milder in sporadic cancers than hereditary cases because of absence of germ-
line mutations (Paz-Elizur et al, 2008). Generally, the response to DNA damage involves 
expression of various genes to repair. Susceptibility to the diseases caused by failure of 
DNA repair can depend on rare mutations in genes involved in DNA repair or on low 
penetrance single nucleotide polymorphisms (SNPs) (Ripperger et al., 2009). Although no 
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clinical decisions can be based on their presence or absence, polymorphisms of DNA repair-
related genes may modulate cancer predisposition (Mocellin et al., 2009). SNPs occur when 
a single nucleotide in the genome sequence is altered; they occur every 100–300 bases along 
the 3 billion base human genome, so they contain about 90% of all human genetic variations 
that are thought to account for many health-related conditions, such as individualized drug 
responsiveness and disease predispositions including cancer (Mocellin et al., 2009, Paz-
Elizur et al, 2008). Even though risks conferred by individual loci are relatively small, some 
risky alleles have been thought to act multiplicatively (Ripperger et al., 2009).  
There are several different loci studied for various kinds of diseases and cancers. Cell cycle 
check-point and DNA repair gene polymorphisms are main foci in those studies. 
8-oxoguanine formation is one of the major mutagenic oxidative DNA lesions, frequently 
used as a measure of oxidative stress. To protect DNA from such a damage, prevention, 
repair or proofreading must be operated; prevention is by avoiding the incorporation by the 
enzyme MTH1 to hydrolyse 8-oxo-dGTP; repair is by excising 8-oxoguanine from DNA by 
OGG1-initiated BER; and proofreading is by removing an adenine misincorporated opposite 
a template 8-oxoG by MUTYH-initiated BER in order to enable conversion of the 
premutagenic 8-oxoG:A mispair into a 8-oxoG:C base pair. BER is applied on oxoguanine 
primarily by 8-oxoguanine DNA glycosylase 1 (OGG1). The most common SNP studied in 
this gene is OGG1Ser326Cys thought to change the phosphorylation status of the enzyme. 
Studies on polymorphism in this gene region and others involved in BER of oxidative DNA 
damage, such as APE1 or XRCC1, concluded no associations with cancer risk (Paz-Elizur et 
al, 2008). XRCC does not related to their biochemical functions; these genes only represent 
components of different damage recovery pathways (Basso et al., 2007). SSBs can be 
repaired by PARPs and XRCC1 (Basso et al., 2007, Ladiges, 2006). XRCC1 is known to have a 
large number of SNPs with its relative high frequency in the population (Basso et al., 2007, 
Au , 2006, Ladiges, 2006). XRCC1 has no enzymatic activity, but has three interactive 
domains: the N-terminal domain (NTD) is the site for POL b binding and also the site for 
direct binding to gapped or nicked DNA. Previously, 27 gene variations of XRCC1 were 
detected, the most frequent ones are R399Q and R194W (Ladiges, 2006). The XRCC1 194W 
allele was recently found to have a protective role against tobacco-related cancers. And the 
XRCC1 399Q allele was shown to behave as a risk factor for tobacco-related cancers in light 
smokers, but as a protective factor in heavy smokers (Basso et al., 2007).  
The Xeroderma pigmentosum complementation group C (XPC) is one of the eight genes in 
the NER pathway; the others are ERCC1, XPA, XPB, XPD, XPE, XPF and XPG. XPC is 
involved in the DNA damage recognition and DNA repair initiation in the NER pathway, 
this is important because the binding of XPC to damaged DNA is the rate-limiting step of 
NER. Normal XPC gene is found to be critical for the cells to complete excision repair of 
bulky DNA lesions including smoking-induced DNA adducts. The results of studies about 
the association of XPC polymorphisms with cancer risk are contradicting (Qui et al., 2008)  
XPD gene product is the adenosine triphosphate-dependent DNA helicase component of the 
transcription factor, TFIIH. The defects in XPD/ERCC2 (the xeroderma pigmentosum group 
D (XPD) gene, also called the excision repair cross-complementing rodent repair deficiency 
group 2 (ERCC2) gene) are the cause of an autosomal recessive skin disorder characterized 
by solar hypersensitivity of the skin exposed to direct sunlight and so it has high risk for 
developing epithelial cancers and melanoma (Mocellin et al., 2009, Manuguerra et al., 2006). 
XPD/ERCC2 is thought to be associated with the likelihood of harboring melanoma. The 
XRCC3 protein is important in DNA DSBs/recombinational repair as a member of Rad51-
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related protein family that is participating in HR to maintain chromosome stability and 
repair DNA damage (Manuguerra et al., 2006). 
Breast cancer is the most common malignancy in women with an average lifetime risk of 8–
10%. Breast cancer risk doubles in the women with a first degree relative with the same 
problem (Ripperger et al., 2009). Germline BRCA1 or BRCA2 mutations account for 20–40% of 
breast cancer in families, and they are associated with a high lifetime risk of 60–85% for breast 
cancer as well as an increased risk for ovarian cancer (Ripperger et al., 2009, Basso et al., 2007). 
In high risk families, some other genes are investigated to find their risk usually concentrating 
on genes involved in DNA repair as CHEK2, RAD50, BRIP1 and PALB2. Cell cycle checkpoint 
kinase 2 (CHEK2) is a signalling component of DNA repair phosphorylating BRCA1. 
Currently, there are several different SNPs in genes or chromosomal loci that have been 
identified in genome-wide association studies and a common SNP in CASP8 was found to 
reduce breast cancer risk (Ripperger et al., 2009).  
Breast cancer cells are thought to be deficient in DSB repair (Ralhan et al., 2007). The 
products of key breast cancer susceptibility genes, BRCA1, BRCA2 (XRCC11), ATM and 
TP53, play important roles in DSB repair and chromosome stability (Ralhan et al., 2007, 
Basso et al., 2007). ATM mutation (7271TG) has been suspected to be associated with an 
increased risk of breast cancer in relatives. The active ATM monomers phosphorylate 
various DSB repair and genome surveillance factors such as Artemis, NBS1, BRCA1, 
Fanconi anemia complementation group D2 protein (FANCD2), p53, p53-binding protein 1 
(53BP1). Recently RAD50 germline mutations have been related to breast cancer 
susceptibility. P53 has several responses simultaneously, modulating DNA repair, blocking 
the cell cycle or inducing apoptosis in irrepairably damaged cells. It inhibits strand exchange 
mediated by RAD51, binds Holliday junctions and detects mispairings in heteroduplex 
junction DNA (Ralhan et al., 2007). 
The polymorphism studies are usually focused on cancer cases. Since the development of 
cancer involves the induction of multiple mutations, recent investigations are usually about 
the interactions of multiple susceptibility genes. But cancer is polygenic and single genetic 
variants are usually insufficient to predict risk of cancer. Consequently, the functional 
significance of these SNPs is still largely unknown. Using established common cancer 
susceptibility SNPs, there are hundreds of possible combinations of genotypes for each 
kinds of cancer in different populations. The studies for SNPs must be enlarged for various 
populations to be reliable.  
5. DNA repair disorders 
DNA repair disorders are usually characterized by X-ray sensitivity, cancer susceptibility, 
immunodeficiency, neurological abnormalities. DNA repair disorders can be in either of 
the repair types. Defects in the NER mechanism are responsible for several genetic 
disorders, including XP (hypersensitivity to sunlight/UV, resulting in increased skin 
cancer incidence and premature aging), Cockayne syndrome (hypersensitivity to UV and 
chemical agents), Trichothiodystrophy (sensitive skin, brittle hair and nails). The latter 
two usually accompanies with mental retardation. XP is an autosomal recessive 
hereditary disease with a prevalence of approximately 1–4 in 106  live births characterized 
by severe predisposition to skin cancer, mainly squamous cell and basal cell carcinoma 
(Basso et al., 2007, Au, 2006). XP cells are defective in NER and known responsible genes 
are XP-A to XP-G (Basso et al., 2007).  
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Other DNA repair disorders include Werner's syndrome with growth retardation and 
premature aging; Bloom's syndrome with skin hypersensitivity and high incidence of 
malignancies and Ataxia telangiectasia(Louis–Bar syndrome) (ATM) with sensitivity to 
some chemicals and ionizing radiation. ATM mutations are found to be responsible for the 
autosomal recessive disease, ataxia teleangiectasia, characterized by cerebellar ataxia, 
telangiectases, immune defects and predisposition to various malignancies (Table 1) 
(Ripperger et al., 2009). The most common DSB repair defects result from deficiencies in the 
ATM and NBS genes. The defects in NBS and DNA Ligase IV genes are chromosomal 
instability syndromes associated with various chromosomal aberrations and translocations 
(Nahas & Gatti, 2009). All those diseases are "progeria syndromes" means "accelerated aging 
diseases" because these patients suffer from aging-related diseases at an abnormally young 
age, while not manifesting all the symptoms of old age.  
Hereditary breast cancer, hereditary colon cancer and Fanconi's anemia are also DNA repair 
diseases. Hereditary breast and ovarian cancer is the most frequent autosomal dominant 
disorder associated with mutations in BRCA1 or BRCA2. Additionally, there are several 
diseases increasing breast cancer risk. For instance, Peutz–Jeghers syndrome, caused by 
heterozygous germline mutations in STK11, is increasing the risk of breast cancer.It is 
mainly a polyposis syndrome characterized by melanocytic macules of the lips, digits as 
well as multiple hamartomatous polyps of gastrointestinal tract. Cowden syndrome is 
another one characterized by multiple hamartomas in skin, gastrointestinal tract, 
endometrium, breast and brain and it is associated with an increased breast cancer risk of up 
to 30–50% by the age of 70 years (Ripperger et al., 2009). Hereditary colon cancer is occuring 
by another defective DNA repair pathway, MMR, causing the predisposition to cancer. This 
condition leads to microsatellite instability (MSI) and frameshift mutations (Basso et al., 
2007). MSI is also a common finding in colorectal tumors of Lynch syndrome patients (Basso 
et al., 2007, Ripperger et al., 2009). MUTYH-associated polyposis (MAP) is another disease 
with strong predisposition to a hereditary form of colorectal cancer, germ-line biallelic 
mutations in the MUTYH gene has been found to be responsible (Paz-Elizur et al, 2008). 
Another interesting disease is Fanconi Anemia, characterized by progressive bone marrow 
failure and multiple congenital abnormalities, which has been suggested to be caused by 
defects in coordination of NER, HR and translesional DNA synthesis (TLS). Fanconi anemia 
can be either autosomal recessive or X-linked recessive cancer susceptibility syndrome 
(Basso et al., 2007, Nahas & Gatti, 2009). Cells taken from Fanconi anemia patients exhibit 
hypersensitivity to mitomycin C, the DNA crosslinking agent. This hypersensitivity to cross-
linking agents increases the risk to create chromosomal abnormalities. The characteristic 
feature for cell lines of patients deficient in DNA repair and chromatin maintenance proteins 
is the increased chromosomal aberration frequency (Nahas & Gatti, 2009). Another 
syndrome, Li–Fraumeni, is caused by germline TP53 mutations, has a high prevalence in 
breast cancer, soft tissue sarcomas, leukaemia and brain tumors in young population 
(Ripperger et al., 2009). There are several different genetic syndromes related to DNA repair, 
and because of the complexity of the repair pathways, various genes are found to be 
responsible from each. There are still some DNA repair syndromes without any known 
defective gene region. The XCIND syndrome comprises the chromosomal instability 
syndromes, the cancer susceptibility syndromes, the DNA DSB repair disorders, and the 
some primary immunodeficiencies (Nahas & Gatti, 2009).  
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SYNDROME GENE 
PRIMARY 
PATHOGENESIS 
PATHWAY PREDISPOSITION 
Ataxia 
Telangiectasia 
ATM ATM protein kinase HR, NHEJ Immunodeficiency, 
cancer 
Fanconi Anemia Fanconi 
anemia 
genes (A, B, 
C, D1, D2, 
E, F, G, I, J, 
L, M), 
Rad50 
Replication Fork/Cell 
Cycle Checkpoint 
Multiple 
pathways, 
crosslinking 
repair 
myelofibrosis, 
leukemia, other 
cancers 
 X-linked 
Agammaglobuline
mia (Bruton) 
BTK BTK gene function NER Immunodeficiency 
Lynch Syndrome 
(Hereditary non-
polyposis 
colorectal cancer : 
HNPCC) 
MLH1, 
MSH2, 
MSH6, 
PMS1, 
PMS2 
DNA repair/cell cycle 
checkpoint 
MMR Colon cancer (70-
85%) 
Endometrial 
carcinoma (50%) 
Other cancers (15%) 
Peutz–Jeghers  STK11 
(LKB1)  
Cell cycle checkpoint Multiple 
pathways 
Gastrointestinal 
hamartomatous 
polyps, breast 
cancer, other cancers 
SCID -ADA ADA 
 
Toxicity of 
deoxyadenosine 
NHEJ Immunodeficiency 
SCID-Artemis artemis DNA end-joining 
repair 
NHEJ Immunodeficiency 
Xeroderma 
Pigmentosum 
XP-A, XP-B  NER UV-induced skin 
cancers 
Nijmegen breakage 
Syndrome 
NBS1 Double strand DNA 
repair 
Multiple 
pathways, 
DSB cell 
signalling 
İmmunodeficiency, 
microcephaly, 
lymphoid 
malignancy 
Multiple colorectal 
adenomas and 
carcinomas with 
no germline APC 
defect 
MUTYH Base excision repair BER İndicating mutations 
in BER genes are 
involved in cancer. 
Werner’s 
Syndrome 
WRN RecQ 
helicase 
Cell cycle checkpoint HR, TLS Premature aging, 
cancer 
Bloom’s Syndrome BLM RecQ 
helicase 
Cell cycle checkpoint HR, TLS Premature aging, 
cancer 
Table 1. Genetic disorders involved in DNA repair pathways  
(Pollard & Gatti, 2009, Howlett et al., 2006, Donahue& Campbell, 2004, Mastrocola&Heinen, 
2010, Pichierri et al., 2011, Masai, 2011) 
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The cause of the most of those XCIND syndromes is not determined, suggesting many new 
DNA repair proteins have yet to be identified. Advanced researches will determine those 
and perhaps even new paths of DNA repair. Those diseases are important to be resolved 
both for their susceptibility for various cancers and their illustrating capacity to understand 
cancer mechanisms and also aging. 
6. DNA repair and cancer therapy 
The genome is continually exposed to mutagenic stress from endogenous and exogenous 
insults that damage DNA (Martin et al., 2008b, Moeller et al., 2009, Liang et al., 2009). DNA 
repair mechanisms play a central role to overcome these damaging effects and maintain 
DNA integrity. Deregulation of the DNA repair mechanisms is associated with the 
development of cancer as well as other diseases (Amir et al., 2010, Megnin-Chanet et al., 
2010). DNA damage repair mechanisms are required to prevent cancer. However, 
incomplete efficiency of these repair mechanisms is also required for genotoxic treatments 
(i.e. chemotherapy and/or radiotherapy) to achieve cure since DNA repair mechanisms 
greatly affect the response to cytotoxic treatments (Moeller et al., 2009, Rowe & Glazer, 
2010). Most of the anticancer therapies lead to DNA damage to trigger death signals in 
cancer cells. The efficacy of cancer therapy is extensively influenced by DNA repair 
capacity. Based on this rationale, inhibitors of DNA repair proteins have been developed in 
cancer therapy, mostly to potentiate the effects of cytotoxic agents (Martin et al., 2008b).  
6.1 DNA repair inhibitors as monotherapy (Synthetic Lethality) 
When mutation of two genes in isolation is compatible with viability, but simultaneous 
mutation is lethal, these two genes are synthetically lethal (Martin et al., 2008b, Moeller et 
al., 2009, Mangerich & Burkle, 2011, Reinhardt et al., 2009a, Rowe & Glazer PM, 2010, 
Helleday et al., 2008). Accordingly, targeting a gene that is synthetic lethal to a cancer-
relevant mutation should kill only malignant cells and preserve normal cells (Mangerich & 
Burkle, 2011). DNA repair is an ideal target for inhibition in cancer cells as the inhibitors 
should be exclusively toxic to cancer cells and be associated with minimal adverse effects for 
patients. Therefore, DNA repair inhibitors have been shown to work as single agents in 
patients with DNA repair defective tumors. The most remarkable example is the use of 
PARP inhibitors to treat patients with inherited breast and ovarian cancers that lack wild-
type copies of BRCA1 and BRCA2 genes. PARP was discovered in 1963 by Chambon and 
his group. It is a multifunctional nuclear protein implicated in detection and signaling of 
DNA strand breaks introduced by oxidative stress, ionizing radiations and cytotoxic agents. 
PARP is involved in multiple cellular processes, such as DNA repair and maintenance of 
genomic integrity, regulation of transcription, epigenetic regulation, chromatin remodeling, 
death via necrosis and apoptosis, regulation of cellular replication and differentiation, 
inflammation, regulation of telomerase activity and protein degradation via ubiquitination. 
(Martin et al., 2008b, Sodhi et al., 2010, Rassool & Tomkinson, 2010, Moeller et al., 2009,). 
PARP-1 is the most studied and the founding member of the PARP family. It is a 116 kDa 
protein having substantially conserved structural and functional organization including an 
N-terminal double zinc finger DNA-binding domain (DBD), a nuclear localization signal, a 
central auto modification domain and a C-terminal catalytic domain (Sodhi et al., 2010, 
Megnin-Chanet et al., 2010, Mangerich & Burkle, 2011). Zinc-finger DBD detects and binds 
to sites of single-stranded DNA damage. PARP1 utilizes NAD+ as a substrate and catalyzes 
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the addition of ADP-ribose polymer side chains to itself, DNA ligase III, DNA polymerase-
ǃ, XRCC1, and other repair components, by that means recruiting and regulating the 
effectors of BER. The presence of PARP1 has been demonstrated to be required for efficient 
functioning of BER (Kupper JH et al., 1997, Sodhi et al., 2010, Mangerich & Burkle, 2011, 
Amir et al., 2010, Rowe & Glazer, 2010). Cells with defective BRCA-1 and BRCA-2 become 
highly dependent on other alternative repair pathways. One of those alternative routes is 
BER. This repair mechanism help prevent the development of DSBs in order to compensate 
for the inability of BRCA-mutant cells to repair DSB in an error-free manner. Inhibition of 
this pathway via PARP1 inhibitors increases the number of unrepaired SSBs, which 
eventually cause the collapse of the replication fork and produces DSBs. As a result, BRCA-
defective cells are hypersensitive to the blockade of BER by the inhibition of PARP1 due to 
dysfunction of DSB repair. The non-tumor cells are better able to tolerate the PARP 
inhibition because their HR pathway is intact (Farmer et al., 2005, McCabe et al., 2005, 
Martin et al., 2008b, Amir et al., 2010, Rowe & Glazer, 2010).  
Cells that are defective in recombination-related proteins other than BRCA1 or BRCA2, such 
as RAD51, RAD54, XRCC2, XRCC3, DSS1, replication protein A1, ATM, ATR, CHK1, CHK2, 
NBS1 and components of the Fanconi anaemia repair pathway, also show increased 
sensitivity to PARP inhibition. This suggests that PARP inhibitors might also be used in 
treating several types of tumors with defects in HR (Bryant et al., 2005, McCabe et al., 2006, 
Bryant & Helleday, 2006, Helleday et al., 2008).  
Several phase I and II trials using PARP inhibitors for patients with breast, ovarian, and a 
variety of other malignancies are currently under way. Olaparib (AZD2281, KU-0059436, 
KuDOS Pharmaceuticals/AstraZeneca, Cambridge, UK) shows low toxicity, and there are 
suggestions of significant antitumor activity, as assessed by radiography and by 
measurement of tumor biomarkers (Yap et al., 2007, Martin et al., 2008b, Rassool & 
Tomkinson, 2010, Mangerich & Burkle, 2011, Amir et al., 2010, Rowe & Glazer, 2010, 
Megnin-Chanet et al., 2010, Helleday et al., 2008). Also, BSI-201 (BiPar Sciences/Sanofi-
aventis, San Francisco, California), ABT-888 (Abbott Labs, Chicago, IL), AG-014699 
(Agouron Pharmaceuticals/Pfizer Inc., La Jolla, CA), MK-4827 (Merck & Co Inc, Whitehouse 
Station, NJ) and Cep-9722 (Abbott Labs, Chicago, IL) are strong inhibitors of PARP-1 and 
they are currently undergoing phase I or II testing both as monotherapy as well as in 
combination with a variety of different chemotherapy regimens.  
Another synthetic lethal interaction has been determined between ATM and p53. Loss of 
ATM or Chk2 strongly increased the sensitivity of p53-deficient cells to doxorubicin-
induced cell death. Inhibition of ATM/Chk2 in p53-deficient tumors provides an elegant 
synthetic lethality-based strategy to sensitize these tumors for DNA-damaging 
chemotherapy (Reinhardt et al., 2007, 2009a).  
The major challenge in the area of synthetic lethal approaches to cancer treatment is the 
identification of new synthetic lethal pairs. Genome-wide RNAi screening and next 
generation sequencing of cell lines and primary tumors should allow the systematic search 
for new synthetic lethal relationships (Rowe & Glazer, 2010).With the exploitation of new 
synthetic lethal approaches it is possible that novel therapeutics can be identified that show 
strong selectivity for tumor cells, yield better response rates and lower toxicity. 
6.2 DNA repair inhibitors in combination therapy 
Several clinical and preclinical studies using PARP inhibitors in combination with cytotoxic 
agents including alkylating agents, topoisomerase inhibitors, DNA-crosslinking agents and 
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ionizing radiation (IR) have been conducted. The data showed that PARP inhibitors 
sensitize malignant cells to all of these agents and to IR. (Martin et al., 2008b, Sodhi et al., 
2010, Mangerich & Burkle A, 2011, Rowe & Glazer PM, 2010, Megnin-Chanet et al., 2010, 
Helleday et al., 2008).  
6.2.1 Alkylating agents 
Temozolomide (TMZ) is an alkylating agent which is used as a single agent or in combination 
with IR in the therapy of glioblastoma multiforme and melanomas (Stupp et al., 2005, 
Mangerich & Burkle, 2011). TMZ can cross the blood brain barrier effectively and display 
limited bone marrow toxicity (Plummer et al., 2005, Mangerich & Burkle, 2011, Helleday et al., 
2008). The therapeutic benefit of TMZ depends on its ability to methylate DNA which occurs 
mostly at N-7 and O-6 position of guanine residues. TMZ also methylates N-3 position of 
adenine. This methylation damages DNA and triggers the death of tumor cells. However, 
some tumor cells show resistance to TMZ by repairing this type of DNA damage and therefore 
diminish therapeutic efficacy of the drug. Tumor cells express O-6 methylguanine-DNA 
methyltransferase (MGMT) in response to drug and subsequently repair O6-methylguanine. 
(Hegi et al., 2005, Martin et al., 2008b, Mangerich & Burkle, 2011, Rowe & Glazer, 2010, 
Megnin-Chanet et al., 2010). A potent oral inhibitor of MGMT O-6(4bromothenyl) guanine has 
been used in combination with TMZ with Phase II trials ongoing in metastatic melanoma and 
colorectal cancer (Hegi et al., 2005). TMZ has been also used in combination with PARP 
inhibitors due to its mechanism of action. Methylation products of TMZ are repaired 
efficiently by BER. PARP activity increases after TMZ administration because of DNA damage 
induction. As PARP inhibition blocks BER, increased cytotoxic lesions become lethal via 
induction of apoptosis. However, TMZ resistance develops if there is a deficiency in the MMR, 
which contributes to TMZ cell killing when functional. MMR is required for the induction of 
DNA strand breaks after the formation of methyl products. PARP inhibitor AG14361 has been 
indicated to restore sensitivity to TMZ in MMR-deficient human colon and ovarian cancer cells 
(Curtin N et al., 2004). 
6.2.2 Platinium drugs  
Cisplatin, carboplatin and oxaliplatin are the most commonly used chemotherapeutic 
compounds in cancer patients (Helleday et al., 2008). These drugs cause inter- and 
intrastrand crosslinks that are repaired by NER. It has been suggested that upregulation of 
ERCC1 expression, is a key enzyme in NER, is associated with the resistance to platinum-
based therapy. ERCC1 inhibitors have therefore been developed to deal with the resistance 
to platinium therapies (Altaha et al., 2004).  
Another resistance to platinum drugs develops due to the silencing of MMR genes by 
hypermethylation. The toxicity of agents such as cisplatin  depends on functional MMR. For 
this reason, DNA demethylating agents such as 2′-deoxy-5-azacytidine (decitabine; MGI 
Pharma, Bloomington, Minnesota, USA) have been combined with platinum compounds to 
reverse drug resistance. Preclinical data from xenograft models and translational studies 
from drug-resistant cells and tissues that are MMR-deficient owing to MLH1 
hypermethylation have demonstrated increased chemotherapeutic efficacy when a 
demethylating agent is combined with platinum chemotherapy (Gifford et al., 2004, Plumb 
et al., 2000). Decitabine is currently being tested in combination with carboplatin in a phase 
II clinical trial in patients with ovarian cancer. 
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PARP1 has a direct role in the repair of damages triggered by platinum compounds. Thus, 
PARP1 inhibitors potentiate the effect of platinum compounds (Bartsch et al., 2010). PARP-1 
inhibitors, in conjunction with platinum derivatives, were found to exhibit significant 
survival benefit over monotherapy in a relatively small phase II study. In this study, data 
were reported from a randomized phase II study of combination chemotherapy with 
carboplatin and gemcitabine with or without PARP1 inhibitor (BSI-201) in patients with 
triple negative breast cancer (O’Shaughnessy et al., 2009). In combined chemotherapy, 
PARP-inhibition is highly attractive, as carboplatin will cause DNA strand-breaks while BSI-
201 will block PARP1-dependent repair (Bartsch et al., 2010). BSI-201 is currently in phase III 
clinical trials for breast cancer and squamous cell lung cancer therapy in combination with 
gemcitabine/carboplatin. 
6.2.3 Topoisomerase inhibitors 
Topoisomerases are a group of enzymes that resolve torsional strains enforced on the 
double helix during DNA replication. Topoisomerase 1(Topo 1) induces transient SSBs by 
forming a covalent DNA-Topo 1 complex (Wang, 2002). Resealing of these breaks restores 
DNA integrity. (Koster et al., 2007, Pommier, 2006). Camptothecins are the inhibitors of 
Topo 1 which target Topo 1-DNA intermediate (Pommier, 2006, Waardenburg et al., 2004). 
Topotecan and irinotecan are the analogs of Camptothecins and they are used as anticancer 
agents in patients with ovarian, cervical and small cell lung cancer (Pommier, 2006). These 
inhibitors reversibly stabilize the covalent Topo 1- DNA intermediate by inhibiting DNA 
relegation. Topo 1-DNA-drug intermediates are converted to lethal lesions due to DSBs 
during replication (Waardenburg et al., 2004).  
PARP1 induces Topo 1 activity in response to DNA damage. Thus, combined therapy of 
Topo1 inhibitors with PARP1 inhibitors may potentiate cytotoxic effects of Topo 1 inhibitors 
(Mangerich & Burkle, 2011, Bowman et al., 2001, Delaney et al., 2000).  
In vitro combination experiments using platinum compounds with Topo 1 inhibitors 
showed a synergic effect in various cell lines (Waardenburg et al., 2004).   
6.2.4 Ionizing radiation  
DNA-dependent protein kinase (DNA-PK) is an essential enzyme in repairing DSBs by NEJ 
following IR. DNA-PK is a member of phosphatidylinositol-3-kinase (PI3K) superfamily. 
After cellular exposures, DNA-PK is autophosphorylated, which is crucial for efficient 
NHEJ. Studies show that cells defective in DNA-PK are highly sensitive to IR which makes 
it an attractive molecular target for cancer therapies (Collis et al., 2005). Currently, a number 
of potent and selective DNA-PK inhibitors are available including Vanillin, Su11752, 
IC87102, IC87361, NU7441, NU7026 and Salvicine (Salles et al., 2006, Hollick et al., 2003, 
Leahy et al., 2004, Ismail et al., 2004).  
PARP1 inhibition might have radiosensitizing effect following IR therapy which creates 
SSBs and DSBs since its inhibition introduces additional cytotoxicity to tumor cells (Dungey 
et al., 2008, Noel et al., 2006).   
6.2.5 ATM inhibition 
Two kinases from (PI3K)-related protein kinase family, ATM and ATR are central to cellular 
response to DSBs. Once the kinases are activated, many proteins are phosphorylated by 
ATM and ATR which initiates a cascade inducing cell-cycle arrest and facilitates DNA 
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repair. ATM inhibition makes tumor cells more sensitive to agents that cause DSBs 
(Helleday et al., 2008). KU55933, an inhibitor of ATM kinase activity, is currently in 
preclinical development.  
PARP-deficient cells have been shown to be sensitive to KU55933 and NU7026, which  
is a DNA-PK inhibitor. Based on this data, a relationship between PARP1, ATM and  
DNA-PK may have value in terms of combination therapy in cancer patients (Bryant & 
Helleday, 2006). 
It now seems likely that an understanding of how DNA damage contributes to 
tumorigenesis and how this damage is repaired can be used to design novel therapeutic 
approaches to cancer. In BRCA-associated cancers, the inhibition of BER with agents such as 
the PARP inhibitors may provide an effective synthetic lethality approach resulting in 
tumor cell death with minimal toxicity to normal tissues. 
Even though the use of PARPi in cancer therapy has received much attention in recent 
years, some issues remain to be addressed carefully in the near future: 
An important question is the issue of long-term safety. A major drawback in the systemic 
long-term treatment with PARP inhibitors is the damage to DNA repair and genomic 
stability in normal cells, which may lead to secondary tumors at later age. Basic research 
into obtaining a more complete picture of all DNA repair pathways and their interplay is 
crucial for solving the existing problems as well as for the future of DNA repair inhibitors in 
cancer therapy. 
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